

AMENDMENTS TO THE CLAIMS

IN THE CLAIMS

The following Listing of Claims, in which deleted text appears ~~struck through~~ and inserted text appears underlined, will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-205. (Canceled)

206. (Previously presented) An oligonucleotide compound consisting of 16 monomers, wherein adjacent monomers are covalently linked by a phosphodiester or a phosphorothioate linkage, and wherein the sequence of the oligonucleotide compound is CTCAatccatggCAGC (SEQ ID NO: 130) or CTCAatccatggCAGc (SEQ ID NO: 130), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers.

207. (Canceled)

208. (Previously presented) The oligonucleotide compound of claim 206, wherein said compound is C₅T₅C₅A₅ast₅c₅c₅ast₅g₅g₅C₅A₅G₅C (SEQ ID NO: 664), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, and wherein the subscript "s" denotes a phosphorothioate linkage.

209. (Canceled)

210. (Currently amended) The oligonucleotide compound of claim 206, wherein said compound is ~~C_oT_oC_oA_oast_oc_oc_oast_og_og_oC_oA_oG_oC~~ C_oT_oC_oA_oast_oc_oc_oast_og_og_oC_oA_oG_oC (SEQ ID NO: 662), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, and wherein the subscript "s" denotes a phosphorothioate linkage and the subscript "o" denotes a phosphodiester linkage.

211. (Canceled)

212. (Previously presented) The oligonucleotide compound of claim 206, wherein said compound is $C_S T_S C_S A_S a s t_s c_s c_s a s t_s g_s g_s C_S A_S G_{S C}$ (SEQ ID NO: 661), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, and wherein the subscript "s" denotes a phosphorothioate linkage.

213. (Previously presented) The oligonucleotide compound of claim 206, wherein said compound is CTCAatccatggCAGC (SEQ ID NO: 130) or CTCAatccatggCAGc (SEQ ID NO: 130), wherein uppercase letters denote beta-D-oxy-LNA monomers, lowercase letters denote DNA monomers, and wherein the cytosine in each cytosine-containing beta-D-oxy-LNA monomer is 5-methyl cytosine.

214. (Canceled)

215. (Previously presented) The oligonucleotide compound of claim 213, wherein said compound is $C_S T_S C_S A_S a s t_s c_s c_s a s t_s g_s g_s C_S A_S G_{S C}$ (SEQ ID NO: 664), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript "s" denotes a phosphorothioate linkage, and wherein the cytosine in each cytosine-containing beta-D-oxy-LNA monomer is 5-methyl cytosine.

216. (Canceled)

217. (Currently amended) The oligonucleotide compound of claim 213, wherein said compound is $C_o T_o C_o A_o a s t_s c_s c_s a s t_s g_s g_s C_o A_o G_o C$ (SEQ ID NO: 662), wherein uppercase letters denote beta-D-oxy-LNA monomers, lowercase letters denote DNA monomers, the subscript "s" denotes a phosphorothioate linkage, the subscript "o" denotes a phosphodiester linkage, and wherein any cytosine in each cytosine-containing beta-D-oxy-LNA monomer is 5-methyl cytosine.

218. (Canceled)

219. (Previously presented) The oligonucleotide compound of claim 213, wherein said compound is $C_S T_S C_S A_S a s t_s c_s c_s a s t_s g_s g_s C_S A_S G_{S C}$ (SEQ ID NO: 661), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript "s" denotes a

phosphorothioate linkage, and wherein the cytosine in each cytosine-containing beta-D-oxy-LNA monomer is 5-methyl cytosine.

220. (Previously presented) The oligonucleotide compound of claim 219, wherein said compound is $^{Me}C_sT_s^{Me}C_sA_sA_sT_sC_sC_sA_sT_sG_sG_s^{Me}C_sA_sG_sc$ (SEQ ID NO: 661), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript "s" denotes a phosphorothioate linkage, and ^{Me}C denotes a beta-D-oxy-LNA monomer containing 5-methyl cytosine.

221-224. (Canceled)